aser immunotherapy with and without topical anti-PD1 in basal cell carcinomas - Laser immunotherapy and topical anti-PD1
- Conditions
- Basal cell carcinoma in 24-30 patientsTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2019-003310-14-DK
- Lead Sponsor
- Department of Dermatology, Bispebjerg Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
•Patients 18 years or older
•Histologically verified BCC, irrespective of histologic subtype with diameter =7 mm at baseline.
•Signed informed consent.
•Female subjects of childbearing potential* must be confirmed not pregnant by a negative pregnancy test prior to study treatment and must use a safe contraceptive method.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10
•Concomitant treatment with 5-FU or imiquimod
•Concomitant chemotherapeutic treatment
•Concomitant systemic immunotherapeutic treatment
•Pregnant or lactating women
•Allergies to anti-PD1
•Patients with a tendency to form keloids
•Other skin diseases or tattoos in the treatment area.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method